Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526588 · ClinicalTrials.gov registry record · Phase 1
Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03526588 is a Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 3 participants.
The verdict
NCT03526588, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
Interventions
- BIOLOGICAL Autologous umbilical cord blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526588
The ClinicalTrials.gov registry entry for NCT03526588 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous umbilical cord blood is the first listed.
NCT03526588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03526588 about?
NCT03526588 is a clinical study titled "Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)". The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
What is the current status of trial NCT03526588?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-08-01. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03526588?
The interventions under investigation include: Autologous umbilical cord blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT03526588?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.